Skip to main content

Advertisement

SpringerLink
Log in

Ivabradine in Management of Heart Failure: a Critical Appraisal

  • Pharmacologic Therapy (W H W Tang, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Elevated resting heart rate has been linked to poor outcomes in patients with chronic systolic heart failure. Blockade of funny current channel with ivabradine reduces heart rate without inotropic effects. Ivabradine was recently approved by US Food and Drug Administration for patients with stable, symptomatic chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≤35 %, who are in sinus rhythm with resting heart rate (HR) ≥ 70 bpm and either are on maximally tolerated doses of beta-blockers, or have a contraindication to beta-blockers. This article will review and evaluate the data supporting the use of ivabradine in patients with HF and explore its mechanisms and physiologic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240–327.

    Article  PubMed  Google Scholar 

  2. Heidenreich PA, Sahay A, Kapoor JR, Pham MX, Massie B. Divergent trends in survival and readmission following a hospitalization for heart failure in the veterans affairs health care system 2002 to 2006. J Am Coll Cardiol. 2010;56(5):362–8.

    Article  PubMed  Google Scholar 

  3. Rush CJ, Campbell RT, Jhund PS, et al. Falling cardiovascular mortality in heart failure with reduced ejection fraction and implications for clinical trials. JACC Heart Fail. 2015;3(8):603–14.

    Article  PubMed  Google Scholar 

  4. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002;287(7):883–9.

    Article  CAS  PubMed  Google Scholar 

  5. Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull. 2009;90:71–84.

    Article  PubMed  Google Scholar 

  6. Jensen MT, Suadicani P, Hein HO, Gyntelberg F. Elevated resting heart rate, physical fitness and all-cause mortality: a 16-year follow-up in the Copenhagen male study. Heart. 2013;99(12):882–7.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008;372(9641):817–21.

    Article  PubMed  Google Scholar 

  8. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation. 1992;85(5):1743–50.

    Article  CAS  PubMed  Google Scholar 

  9. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103(10):1428–33.

    Article  CAS  PubMed  Google Scholar 

  10. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial. Eur Heart J. 2005;26(21):2259–68.

    Article  CAS  PubMed  Google Scholar 

  11. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009;150(11):784–94.

    Article  PubMed  Google Scholar 

  12. Flannery G, Gehrig-Mills R, Billah B, Krum H. Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. Am J Cardiol. 2008;101(6):865–9.

    Article  CAS  PubMed  Google Scholar 

  13. Franke J, Wolter JS, Meme L, et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed? Clin Res Cardiol Off J German Card Soc. 2013;102(1):23–31.

    Article  CAS  Google Scholar 

  14. Franke J, Schmahl D, Lehrke S, et al. Adjuvant use of ivabradine in acute heart failure due to myocarditis. Case Rep Med. 2011;2011:203690.

    PubMed Central  PubMed  Google Scholar 

  15. Elder DH, Mohan M, Cochrane L, Charles H, Lang CC. Characterizing patients with chronic heart failure in community care after hospitalization: a potential role for ivabradine. Cardiovasc Ther. 2015;33(3):104–8.

    Article  CAS  PubMed  Google Scholar 

  16. Cullington D, Goode KM, Cleland JG, Clark AL. Limited role for ivabradine in the treatment of chronic heart failure. Heart. 2011;97(23):1961–6.

    Article  CAS  PubMed  Google Scholar 

  17. FDA approves Corlanor to treat heart failure. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm442978.htm. Accessed 2015/9/15, 2015.

  18. Sulfi S, Timmis AD. Ivabradine—the first selective sinus node I(f) channel inhibitor in the treatment of stable angina. Int J Clin Pract. 2006;60(2):222–8. 10//received 12//accepted.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Amgen. Corlanor prescribing information. 2015.

  20. Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J. 2013;34(29):2263–70. This is a pooled analysis of two major trials of Ivabradine in left ventricular systolic dysfunction.

    Article  CAS  PubMed  Google Scholar 

  21. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart. 2014;100(19):1506–10. This is a metaanalysis of atrial fibrillation associated wit ivabradine.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Chen SL, Hu ZY, Zuo GF, Li MH, Li B. I(f) current channel inhibitor (ivabradine) deserves cardioprotective effect via down-regulating the expression of matrix metalloproteinase (MMP)-2 and attenuating apoptosis in diabetic mice. BMC Cardiovasc Disord. 2014;14:150.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Becher PM, Lindner D, Miteva K, et al. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and beta-receptor blockade. Hypertension. 2012;59(5):949–57.

    Article  CAS  PubMed  Google Scholar 

  24. Fang Y, Debunne M, Vercauteren M, et al. Heart rate reduction induced by the if current inhibitor ivabradine improves diastolic function and attenuates cardiac tissue hypoxia. J Cardiovasc Pharmacol. 2012;59(3):260–7.

    Article  CAS  PubMed  Google Scholar 

  25. Rienzo M, Melka J, Bize A, et al. Ivabradine improves left ventricular function during chronic hypertension in conscious pigs. Hypertension. 2015;65(1):122–9.

    Article  CAS  PubMed  Google Scholar 

  26. Yue-Chun L, Teng Z, Na-Dan Z, et al. Comparison of effects of ivabradine versus carvedilol in murine model with the coxsackievirus B3-induced viral myocarditis. PLoS One. 2012;7(6):e39394.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Li YC, Luo Q, Ge LS, et al. Ivabradine inhibits the production of proinflammatory cytokines and inducible nitric oxide synthase in acute coxsackievirus B3-induced myocarditis. Biochem Biophys Res Commun. 2013;431(3):450–5.

    Article  CAS  PubMed  Google Scholar 

  28. Milliez P, Messaoudi S, Nehme J, Rodriguez C, Samuel JL, Delcayre C. Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol. 2009;296(2):H435–41.

    Article  CAS  PubMed  Google Scholar 

  29. Vaillant F, Timour Q, Descotes J, et al. Ivabradine induces an increase in ventricular fibrillation threshold during acute myocardial ischemia: an experimental study. J Cardiovasc Pharmacol. 2008;52(6):548–54.

    Article  CAS  PubMed  Google Scholar 

  30. Vaillant F, Dehina L, Mazzadi A, et al. Heart rate reduction with ivabradine increases ischaemia-induced ventricular fibrillation threshold: role of myocyte structure and myocardial perfusion. Resuscitation. 2011;82(8):1092–9.

    Article  CAS  PubMed  Google Scholar 

  31. Langenbach MR, Schmitz-Spanke S, Brockert M, et al. Comparison of a beta-blocker and an If current inhibitor in rabbits with myocardial infarction. J Cardiovasc Surg. 2006;47(6):719–25.

    CAS  Google Scholar 

  32. Choi HY, Noh YH, Cho SH, et al. Evaluation of pharmacokinetic and pharmacodynamic profiles and tolerability after single (2.5, 5, or 10 mg) and repeated (2.5, 5, or 10 mg bid for 4.5 days) oral administration of ivabradine in healthy male Korean volunteers. Clin Ther. 2013;35(6):819–35.

    Article  CAS  PubMed  Google Scholar 

  33. Jiang J, Tian L, Huang Y, Li Y, Xu L. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study. Clin Ther. 2013;35(12):1933–45.

    Article  CAS  PubMed  Google Scholar 

  34. Steg P, Lopez-de-Sa E, Schiele F, et al. Safety of intravenous ivabradine in acute ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a randomized, placebo-controlled, double-blind, pilot study. Eur Heart J Acute Cardiovasc Care. 2013;2(3):270–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Rayan M, Tawfik M, Alabd A, Gamal A. Ivabradine, a novel heart rate slower: is it a sword of double blades in patients with idiopathic dilated cardiomyopathy? Anadolu Kardiyoloji Dergisi: AKD Anatol J Cardiol. 2011;11(5):402–6.

    Google Scholar 

  36. Volterrani M, Cice G, Caminiti G, et al. Effect of carvedilol, ivabradine or their combination on exercise capacity in patients with heart failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218–24.

    Article  PubMed  Google Scholar 

  37. Riccioni G, Masciocco L, Benvenuto A, et al. Ivabradine improves quality of life in subjects with chronic heart failure compared to treatment with beta-blockers: results of a multicentric observational APULIA study. Pharmacology. 2013;92(5–6):276–80.

    Article  CAS  PubMed  Google Scholar 

  38. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875–85.

    Article  CAS  PubMed  Google Scholar 

  39. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Tavazzi L. Rationale and design of a randomized, double-blind, placebo-controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I(f) Inhibitor Ivabradine Trial (SHIFT). Eur J Heart Fail. 2010;12(1):75–81.

    Article  CAS  PubMed  Google Scholar 

  40. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9641):807–16.

    Article  CAS  PubMed  Google Scholar 

  41. Zugck C, Martinka P, Stockl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31(9):961–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–36.

    Article  CAS  PubMed  Google Scholar 

  43. Sabbah HN, Gupta RC, Kohli S, Wang M, Zhang K, Rastogi S. Heart rate reduction with ivabradine improves left ventricular function and reverses multiple pathological maladaptations in dogs with chronic heart failure. ESC Heart Fail. 2014;1(2):94–102.

    Article  Google Scholar 

  44. Tardif JC, O’Meara E, Komajda M, et al. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32(20):2507–15.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Reil JC, Tardif JC, Ford I, et al. Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol. 2013;62(21):1977–85. This substudy of SHIFT provides evidence for the effects of ivabradine on LV unloading.

    Article  CAS  PubMed  Google Scholar 

  46. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62(15):1330–8.

    Article  CAS  PubMed  Google Scholar 

  47. Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med. 2015;16(9):603–9.

    Article  CAS  Google Scholar 

  48. Bonadei I, Sciatti E, Vizzardi E, D’Aloia A, Metra M. Ivabradine during cardiogenic shock: a clinical case and review of the literature. Heart Lung J Crit Care. 2015;44(1):57–8.

    Article  Google Scholar 

  49. Zwicker C, Becker M, Lepper W, Koch KC, Westenfeld R. Cardiogenic shock due to tachycardiomyopathy after heart transplantation: successful treatment with ivabradine. Cardiology. 2010;116(3):174–7.

    Article  CAS  PubMed  Google Scholar 

  50. Roubille F, Lattuca B, Busseuil D, et al. Is ivabradine suitable to control undesirable tachycardia induced by dobutamine in cardiogenic shock treatment? Med Hypotheses. 2013;81(2):202–6.

    Article  CAS  PubMed  Google Scholar 

  51. Nuding S, Ebelt H, Hoke RS, et al. Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol Off J German Card Soc. 2011;100(10):915–23.

    Article  CAS  Google Scholar 

  52. Krahn AD, Yee R, Klein GJ, Morillo C. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol. 1995;6(12):1124–8.

    Article  CAS  PubMed  Google Scholar 

  53. Calo L, Rebecchi M, Sette A, et al. Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia. Heart Rhythm Off J Heart Rhythm Soc. 2010;7(9):1318–23.

    Article  Google Scholar 

  54. Benezet-Mazuecos J, Rubio JM, Farre J, Quinones MA, Sanchez-Borque P, Macia E. Long-term outcomes of ivabradine in inappropriate sinus tachycardia patients: appropriate efficacy or inappropriate patients. Pacing Clin Electrophysiol PACE. 2013;36(7):830–6.

    Article  PubMed  Google Scholar 

  55. Doesch AO, Ammon K, Konstandin M, et al. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation. 2009;88(6):835–41.

    Article  PubMed  Google Scholar 

  56. Doesch AO, Mueller S, Erbel C, et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study. Drug Des Dev Ther. 2013;7:1323–8.

    Article  Google Scholar 

  57. Lage-Galle E, Romero-Rodriguez N, Nevado-Portero J, et al. Safety and effectiveness of ivabradine after cardiac transplantation. Transplant Proc. 2010;42(8):3191–2.

    Article  CAS  PubMed  Google Scholar 

  58. Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol. 2012;59(22):1938–45.

    Article  CAS  PubMed  Google Scholar 

  59. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145(2):292–9.

    Article  PubMed  Google Scholar 

  60. Packer M, Colucci WS, Sackner-Bernstein JD, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94(11):2793–9.

    Article  CAS  PubMed  Google Scholar 

  61. Ordu S, Yildiz BS, Alihanoglu YI, et al. Effects of ivabradine therapy on heart failure biomarkers. Cardiol J. 2015;22(5):501–9.

    Article  PubMed  Google Scholar 

  62. Cullington D, Goode KM, Clark AL, Cleland JG. Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target? Eur J Heart Fail. 2012;14(7):737–47.

    Article  CAS  PubMed  Google Scholar 

  63. Takahama H, Yokoyama H, Kada A, et al. Extent of heart rate reduction during hospitalization using beta-blockers, not the achieved heart rate itself at discharge, predicts the clinical outcome in patients with acute heart failure syndromes. J Cardiol. 2013;61(1):58–64.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Advanced Heart Failure and Transplantation Center, Harrington Heart & Vascular Institute, Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, 11100 Euclid Avenue, Cleveland, OH, 44106, USA

    Gabriela Orasanu, Sadeer G. Al-Kindi & Guilherme H. Oliveira

Authors
  1. Gabriela Orasanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sadeer G. Al-Kindi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guilherme H. Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guilherme H. Oliveira.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Pharmacologic Therapy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orasanu, G., Al-Kindi, S.G. & Oliveira, G.H. Ivabradine in Management of Heart Failure: a Critical Appraisal. Curr Heart Fail Rep 13, 60–69 (2016). https://doi.org/10.1007/s11897-016-0276-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-016-0276-x

Keywords

Search

Navigation